enasidenib
servier,bms
['enasidenib', 'improve', 'aml,(-streamline),(-seamless),(-kamloops)', 'idhentify']
overall survival byidh2 mutant allele (r140 or r172) in patients with rr #aml rx with enasidenib or conventional care regimens in the phase 3 idhentify trial. improved os with ena in idh2 r140 vs ccr (p &lt; 0.01) #asco22 
Assistant Professor @MayoCancerCare @MayoClinic Alumni @MDAndersonNews. Interest in Acute Leukemia and Chronic myeloid disorders. Views are my own